These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22043044)

  • 1. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene profiling assay and application: the predictive role in primary therapy.
    Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
    J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
    Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
    Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.
    Generali D; Symmans WF; Berruti A; Fox SB
    J Natl Cancer Inst Monogr; 2011; 2011(43):99-102. PubMed ID: 22043052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Metzger-Filho O; de Azambuja E
    J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
    Chow LW
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
    Biganzoli L; Claudino WM; Pestrin M; Pozzessere D; Di Leo A
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):1-8. PubMed ID: 17317203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
    Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
    Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies.
    Viale G; Ghioni M; Mastropasqua MG
    Curr Opin Oncol; 2010 Nov; 22(6):541-6. PubMed ID: 20827197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.